Treatment of social phobia with gabapentin: A placebo-controlled study

Journal of Clinical Psychopharmacology

Volumn 19, Issue 4, 1999, Pages 341-348

  Pande, Atul C ^a   Davidson, Jonathan R T ^b   Jefferson, James W ^c   Janney, Carol A ^a   Katzelnick, David J ^c   Weisler, Richard H ^a   Greist, John H ^c   Sutherland, Suzanne M ^b  

^a PFIZER INC   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Dean Found Hlth   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLATULENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SOCIAL PHOBIA; SOMNOLENCE; VERTIGO; XEROSTOMIA;

ACETIC ACIDS; ADULT; AMINES; ANTI-ANXIETY AGENTS; CYCLOHEXANECARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PHOBIC DISORDERS; TREATMENT OUTCOME;

EID: 0032789136     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199908000-00010     Document Type: Article

References (41)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1993;51:8-19.
2. Boyd JH, Rae DS, Thompson JW, Burns BJ, Bourdon K, Locke BZ, Regier DA. Phobia prevalence and risk factors. Soc Psychiatry Psychiatr Epidemiol 1990;25:314-23.
3. Schneier FR, Johnson J, Horning CD, Liebowitz MR, Weissman MR. Social phobia: comorbidity and morbidity in an epidemiological sample. Arch Gen Psychiatry 1992;49:282-8.
4. Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon BA, Gitow A, Sreet L, Del Bene D, Liebowitz MR. Functional impairment in social phobia. J Clin Psychiatry 1994;55:322-31.
5. Van Ameringen M, Mancini C, Styan G, Donison D. Relationship of social phobia with other psychiatric illnesses. J Affect Disord 1991;32:93-9.
6. Weissman MM, Bland RC, Canino GJ, Greenwald S, Lee CK, Newman SC, Rubio-Stipec M, Wickramaratne PJ. The cross-national epidemiology of social phobia: a preliminary report. Int Clin Psychopharmacol 1996;11[suppl 3]:15-23.
7. Judd LL. Social phobia: a clinical overview. J Clin Psychiatry 1994;55[suppl]:5-9.
8. Christenson GA, Mackenzie TR. Social phobia: recognizing the distress signals. Postgrad Med 1989;86:197-202.
9. Bisserbe JC, Weiller E, Boyer P, Lepine JP, Lecrubier Y. Social phobia in primary care: level of recognition and drug use. Int Clin Psychopharmacol 1996;11[suppl]:25-8.
10. Swinson RP, Cox BJ, Woszczyna CB. Use of medical services and treatment for panic disorder with agoraphobia and for social phobia. Can Med Assoc J 1992;147:878-83.
11. Jefferson JW. Social phobia: a pharmacological treatment overview. J Clin Psychiatry 1995;56[suppl]:18-24.
12. Fava GA, Grandi S, Canestrari R. Treatment of social phobia by homework exposure. Psychother Psychosom 1989;2:209-13.
13. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ. Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry 1991;48:938-45.
14. Liebowitz MR, Schneier FR, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, Klein DF. Phenelzine vs. atenolol in social phobia: a controlled comparison. Arch Gen Psychiatry 1992;49:290-300.
15. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 1995;152:1368-71.
16. Van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia: a double-blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 1994;115: 128-34.
17. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 1992;161:353-60.
18. The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 1997;247:71-80.
19. Fahlen T, Nilsson HL, Borg K, Humble M, Pauli U. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine: a double-blind placebo-controlled study. Acta Psychiatr Scand 1995;92:351-8.
20. Lott M, Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Katz RJ, Schaettle SC. Brofaromine for social phobia: a multi-center, placebo-controlled, double-blind study. J Clin Psychopharmacol 1997;17:255-60.
21. Davidson JRT, Potts N, Richichi E, Krishnan R, Ford SM, Smith RM, Wilson WH. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13:423-8.
22. Stein MB, Chartier MJ, Hazen AL, Kroft CD, Chale RA, Cote D, Walker JR. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind, placebo-controlled discontinuation. J Clin Psychopharmacol 1996;16:218-22.
23. Van Vliet IM, Den Boer JA, Westenberg HG, Pian KL. Clinical effects of buspirone in social phobia: a double-blind, placebo-controlled study. J Clin Psychiatry 1997;58:164-8.
24. Taylor CP. Gabapentin: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs, 4th ed. New York: Raven Press, 1995:829-12.
25. Singh L, Field MJ, Ferris P, Hunter JC, Oles RJ, Williams RG, Woodruff GN. The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by d-serine. Psychopharmacology (Berl) 1996;127:1-9.
26. Dimond KR, Pande AC, LaMoreaux L, Pierce MW. Effects of gabapentin (Neurontin) on mood and well-being in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1996;20: 407-17.
27. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141-73.
28. Liebowitz MR. Pharmacotherapy of social phobia. J Clin Psychiatry 1993;54[suppl]:31-5.
29. Davidson JRT, Potts NLS, Richichi EA, Ford SM, Krishnan KRR, Smith RD, Wilson W. The brief social phobia scale. J Clin Psychiatry 1993;52[suppl]:48-51.
30. Marks I, Mathews A. Brief standard self-rating for phobia patients. Behav Res Ther 1979;17:263-7.
31. Hamilton MW. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-60.
32. Hamilton MW. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:10-6.
33. SAS Institute, Inc. SAS/STAT® Software changes and enhancements through release 6.12. Cary, NC: SAS Institute, Inc., 1997.
34. Galpern WR, Miller LG, Greenblatt DJ, Szabo GK, Browne TR, Shader RI. Chronic benzodiazepine administration. IX. Attenuation of alprazolam discontinuation effects by carbamazepine. Biochem Pharmacol 1991;42[suppl]:S99-S104.
35. Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J Psychiatry 1990;35:249-50.
36. Roy-Byrne PP, Ward NG, Donnelly PJ. Valproate in anxiety and withdrawal syndromes. J Clin Psychiatry 1989;50[suppl]:44-8.
37. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and outcome. Arch Gen Psychiatry 1991;48:448-52.
38. Tancer ME. Neurobiology of social phobia. J Clin Psychiatry 1993;54[suppl]:26-30.
39. Rao ML, Clarenbach P, Vahlensieck M, Krätzschmar S. Gabapentin augments whole blood serotonin in healthy young men. J Neural Transm 1988;73:129-34.
40. Schlicker E, Reimann W, Gothert M. Gabapentin decreases monoamine release without affecting acetylcholine release in the brain. Arzneimittelforschung 1985;35:1347-9.
41. Ben-Menachem E, Soderfelt B, Hamberger A, Hedner T, Persson LI. Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures. Epilepsy Res 1995;21:231-6.